An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...
An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...
Geographic atrophy is a growing worldwide health issue, with approximately 8 million patients impacted, according to a ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The Brighterside of News on MSN
Tiny eye implant could restore vision lost to macular degeneration
In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...
Some foods have beneficial properties, whereas others can cause harm, especially where geographic atrophy (GA) is concerned. The dietary choices you make can accelerate the progression of this ...
Maybe you’ve noticed that you can no longer see your friends and family clearly. Or perhaps it’s becoming increasingly hard — if not impossible — to drive yourself to your favorite restaurant.
The "Geographic Atrophy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback